MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)

Mirum and Incyte's zilurgisertib reduced new bone lesion formation in rare disease FOP, and the FDA has begun Priority Review of the NDA with a decision date set for Sept. 26, 2026. The regulatory milestone is supportive for the drug's approval path and suggests meaningful progress in a high-unmet-need indication. The news is positive for the companies, though near-term market impact is likely limited to the stocks rather than the broader market.

Analysis

Mirum and Incyte's zilurgisertib reduced new bone lesion formation in rare disease FOP, and the FDA has begun Priority Review of the NDA with a decision date set for Sept. 26, 2026. The regulatory milestone is supportive for the drug's approval path and suggests meaningful progress in a high-unmet-need indication. The news is positive for the companies, though near-term market impact is likely limited to the stocks rather than the broader market.